sur Jaguar Health, Inc. (NASDAQ:JAGX)
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
Jaguar Health, Inc. (NASDAQ:JAGX) has announced that it regained compliance with Nasdaq's minimum bid price requirement as of June 25, 2024. The company’s securities will continue to be listed and traded on the Nasdaq stock exchange.
The company aims to report results from its pivotal phase 3 OnTarget trial for its cancer supportive care drug crofelemer by July 23, 2024. This development marks a significant milestone for Jaguar Health's ongoing efforts in the pharmaceutical field.
Jaguar Health's president and CEO, Lisa Conte, expressed satisfaction with the compliance news, emphasizing the value of their Nasdaq listing. An investor webcast is scheduled for on or before July 23, 2024, during which updates on the cancer supportive care portfolio will be discussed.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Jaguar Health, Inc.